| ISSN |
2307-8960 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2021. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Endocrinology & Metabolism |
| Manuscript Type |
Case Report |
| Article Title |
Sodium-glucose co-transporter-2 inhibitor-associated euglycemic diabetic ketoacidosis that prompted the diagnosis of fulminant type-1 diabetes: A case report
|
| Manuscript Source |
Unsolicited Manuscript |
| All Author List |
Taro Yasuma, Yuko Okano, Soichiro Tanaka, Kota Nishihama, Kazuhito Eguchi, Chisa Inoue, Kanako Maki, Akihiro Uchida, Mei Uemura, Toshinari Suzuki, Corina N D'Alessandro-Gabazza, Esteban C Gabazza and Yutaka Yano |
| ORCID |
|
| Funding Agency and Grant Number |
|
| Corresponding Author |
Esteban C Gabazza, MD, PhD, Director, Director, Full Professor, Department of Immunology, Mie University Faculty and Graduate School of Medicine, Edobashi 2-174, Tsu 514-8507, Japan. gabazza@doc.medic.mie-u.ac.jp |
| Key Words |
Euglycemic diabetic ketoacidosis; Sodium-glucose cotransporter 2 inhibitors; Fulminant type 1 diabetes; Case report |
| Core Tip |
Fulminant type 1 diabetes mellitus (FT1DM) is characterized by a rapid functional loss of islet β cells and ketoacidosis. Herein, we report a rare case of FT1DM wrongly diagnosed by a medical practitioner as a type 2 diabetes mellitus for the absence of circulating autoantibodies and treated with an oral sodium-glucose co-transporter 2 (SGLT2) inhibitor. This treatment was associated with diabetic symptoms and euglycemic diabetic ketoacidosis. Insulin therapy and SGLT2 inhibitor withdrawal ameliorated the patient's clinical condition. This case report underscores the importance of considering FT1DM in patients with negative circulating autoantibodies and hyperglycemia that develop euglycemic diabetic ketoacidosis during SGLT2 inhibitor treatment. |
| Publish Date |
2021-04-22 12:14 |
| Citation |
Yasuma T, Okano Y, Tanaka S, Nishihama K, Eguchi KC, Inoue CC, Maki KC, Uchida A, Uemura MC, Suzuki T, D'Alessandro-Gabazza CN, Gabazza EC, Yano Y. Sodium-glucose co-transporter-2 inhibitor-associated euglycemic diabetic ketoacidosis that prompted the diagnosis of fulminant type-1 diabetes: A case report. World J Clin Cases 2021; 9(13): 3163-3169 |
| URL |
https://www.wjgnet.com/2307-8960/full/v9/i13/3163.htm |
| DOI |
https://dx.doi.org/10.12998/wjcc.v9.i13.3163 |
